Close Menu

NEW YORK—Agilent Technologies reported after the close of the market on Monday that its fiscal fourth quarter revenues increased 8 percent year over year.

For the three months ended Oct. 31, revenues rose to $1.48 billion from $1.37 billion in Q4 of 2019, beating the average Wall Street estimate of $1.4 billion. The company said core revenues, which exclude the impact of currency and acquisitions and divestitures within the past 12 months, grew 6 percent year over year in Q4.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.